Allergan plc.s in-depth stock price analysis indicates that the stock price has rallied 28.46% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 3.54% . Looking at the past 52 week period, the stock price is down -12.17% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Allergan plc. has a negative value of -21.65 compared to overall market performance. Allergan plc. (NYSE:AGN) has climbed 6.71% in the past week and advanced 13.98% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 5.85% and the outperformance has advanced to 11.94% for the last 4 weeks period.
Allergan plc. (NYSE:AGN) : On Friday heightened volatility was witnessed in Allergan plc. (NYSE:AGN) which led to swings in the share price. The stock opened for trading at $245.5 and hit $247.1899 on the upside , eventually ending the session at $246.36, with a gain of 0.28% or 0.68 points. The heightened volatility saw the trading volume jump to 3,084,426 shares. The 52-week high of the share price is $301.32 and the company has a market cap of $92,373 million. The 52-week low of the share price is at $184.5 .
Allergan plc Ordinary Shares Last issued its quarterly earnings results on Feb 8, 2017. The company reported $3.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.16. Analyst had a consensus of $3.74. The company had revenue of $3864.00 million for the quarter, compared to analysts expectations of $3773.67 million. The companys revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.41 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by Mizuho on Feb 9, 2017 to Buy, Raises Price Target to $ 275 from a previous price target of $273 .Allergan plc Ordinary Shares was Reiterated by Credit Suisse on Dec 9, 2016 to Outperform, Lowers Price Target to $ 274 from a previous price target of $301 .Allergan plc Ordinary Shares was Reiterated by Mizuho on Nov 17, 2016 to Buy, Lowers Price Target to $ 273 from a previous price target of $293 .
Company has reported several Insider transactions to the SEC, on Dec 9, 2016, Nesli Basgoz (director) sold 500 shares at 188.72 per share price.On Nov 21, 2016, Brent L Saunders (CEO) purchased 5,250 shares at 189.13 per share price.On Nov 15, 2016, Maria Teresa Hilado (CFO) purchased 1,422 shares at 210.68 per share price.
Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.